Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices

By Emiko Petrosky, J. Bocchini, S. Hariri, H. Chesson, C. R. Curtis, M. Saraiya, E. Unger, L. Markowitz. MMWR. Morbidity and mortality weekly report, 2015

1,120 citations recorded by the source corpus.

During its February 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended 9-valent human papillomavirus (HPV) vaccine (9vHPV) (Gardasil 9, Merck and Co., Inc.) as one of three HPV vaccines that can be used for routine vaccination. HPV vaccine is recommended for routine vaccination at age 11 or 12 years. ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously. Vaccination is also recommended through age 26 years for men who have sex with men and for immunocompromised persons (including those with HIV infection) if not vaccinated previously. 9vHPV is a noninfectious, virus-like particle (VLP) vaccine. Similar to quadrivalent HPV vaccine (4vHPV), 9vHPV contains HPV 6, 11, 16, and 18 VLPs. In addition, 9vHPV contains HPV 31, 33, 45, 52, and 58 VLPs. 9vHPV was approved by the Food and Drug Administration (FDA) on December 10, 2014, for use in females aged 9 through 26 years and males aged 9 through 15 years. For these recommendations, ACIP reviewed additional data on 9vHPV in males aged 16 through 26 years. 9vHPV and 4vHPV are licensed for use in females and males. Bivalent HPV vaccine (2vHPV), which contains HPV 16, 18 VLPs, is licensed for use in females. This report summarizes evidence considered by ACIP in recommending 9vHPV as one of three HPV vaccines that can be used for vaccination and provides recommendations for vaccine use.

View Paper: https://www.semanticscholar.org/paper/591ea553d97d6f634ead117b1066cf94d6494905

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Viens Lj
Henley Sj
L. Markowitz
M. Watson
M. Saraiya
N. Colombo
Cheryll C. Thomas
T. Thompson

Citations in the corpus

Human Papillomavirus-Associated Cancers - United States, 2008-2012. (2016, background): “The Advisory Committee on Immunization Practices recommends routine vaccination with any of the available HPV vaccines (bivalent, quadrivalent, or 9-valent) for females and quadrivalent or 9-valent for males (5).”
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Furthermore, 9vHPV covers 5 more oncogenic HPV viruses (HPV 31, 33, 45, 52 and 58) in addition to the types already included in 4vHPV, which cause an additional 15% of HPV-related cancers in women and 4% of those in men [4].”
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014 (2015, background): “HHS region and state/ local area ≥1 Tdap§ % (95% CI)¶¶ ≥1 MenACWY¶ % (95% CI) ≥1 HPV** % (95% CI) ≥2 HPV†† % (95% CI) ≥3 HPV§§ % (95% CI) ≥1 HPV** % (95% CI) ≥2 HPV†† % (95% CI) ≥3 HPV§§ % (95% CI) United States overall 87.6 (±0.9)*** 79.3 (±1.1)*** 60.0 (±1.9)*** 50.3 (±1.9)*** 39.7 (±1.9)*** 41.7 ”